Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Cisapride class-action suit approved

Pauline Comeau
CMAJ February 27, 2007 176 (5) 615; DOI: https://doi.org/10.1503/cmaj.070156
Pauline Comeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association or its licensors

An Ontario Superior Court Justice has certified a class-action lawsuit against Johnson & Johnson, its Canadian subsidiary, Janssen-Ortho Inc. and the Attorney General of Canada, on behalf of Canadians who took the antireflux drug cisapride (Prepulsid).

Cisapride made headlines in March 2000 when Vanessa Young, 15, of Oakville, Ont. died of a heart arrhythmia after taking the drug to ease bloating related to bulimia. Cisapride was contraindicated for patients with bulimia.

Cisapride was pulled from the North American market a few months later. A coroner's jury ruled in 2001 that Young died of heart arrhythmia caused, at least in part, by cisapride toxicity. The jury made 50-plus recommendations, including mandatory reporting of adverse drug reactions by health care professionals and clear label warnings of contraindications. None of the major recommendations have been implemented.

An estimated 350 000 Canadians took cisapride. Lawyers involved in the case say thousands may have experienced adverse effects. In 2004, Johnson & Johnson agreed to pay up to $90 million to settle US lawsuits involving more than 300 deaths and 16 000 injuries related to cisapride. The company has argued that physicians failed to properly prescribe the drug, especially to children.

The Canadian class action claims the company failed “to adequately warn Canadian physicians and their patients of the risks associated with ingesting [cisapride]” despite knowledge of serious problems, and that there was little scientific evidence the drug even worked.

The lead plaintiff, 69-year-old Aline Boulanger of Timmins, Ont. was prescribed prepulsid in 1995 and suffered chest pains and shortness of breath. She was diagnosed with ventricular tachycardia with prolonged QT interval that was linked to the use of cisapride. She continues to require heart medication.

Since Vanessa Young's death, her father, Terrence Young, has been an outspoken advocate for drug safety reform. He says he hopes the class-action case, which is not expected to begin for a year or more (and only if litigants don't settle out of court), will force changes in how doctors report adverse drug effects and how Health Canada manages drug safety issues.

“The delay in this case should show the federal government that the courts are a totally inadequate way to deal with prescription drug safety,” says Young.

When asked to comment, a spokesperson for Janssen-Ortho Inc. faxed a brief statement to the CMAJ indicating it had served notice of intent to appeal the decision and that the company believes the drug “is a safe and effective medicine when prescribed appropriately.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 176 (5)
CMAJ
Vol. 176, Issue 5
27 Feb 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cisapride class-action suit approved
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cisapride class-action suit approved
Pauline Comeau
CMAJ Feb 2007, 176 (5) 615; DOI: 10.1503/cmaj.070156

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Cisapride class-action suit approved
Pauline Comeau
CMAJ Feb 2007, 176 (5) 615; DOI: 10.1503/cmaj.070156
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What to know about Omicron XBB.1.5
  • Could a flu shot push help curb pediatric hospitalizations?
  • Stalemate: What’s holding up a new health accord?
Show more News

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Medicine & the law (including forensic medicine)

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire